Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acute Reno-Cardiac Action of Dapagliflozin in Advanced Heart Failure Patients on Heart Transplant Waiting List
2020-005713-40Phase 2Active
- Sponsor
- Hospices Civils de Lyon
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in heart failure (HF) comparing Dapagliflozin with Placebo (2 arms). Primary endpoint: Change in suPAR level from baseline to 6 months. Started May 2021; status: active.
02
Drugs
dapagliflozin
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on 2020-005713-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005713-40.